Analytical Data
-
Gene name
AAGAB
- Application
-
Alternative Names
AAGAB；Alpha- and gamma-adaptin-binding Protein p34
-
Species
Human
-
Source
E. coli
-
Tag
C-his
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q6PD74
-
Expression Region
1-315aa
-
AA Sequence
MAAGVPCALV TSCSSVFSGD QLVQHILGTE DLIVEVTSND AVRFYPWTID NKYYSADINL CVVPNKFLVT AEIAESVQAF VVYFDSTQKS GLDSVSSWLP LAKAWLPEVM ILVCDRVSED GINRQKAQEW CIKHGFELVE LSPEELPEED DDFPESTGVK RIVQALNANV WSNVVMKNDR NQGFSLLNSL TGTNHSIGSA DPCHPEQPHL PAADSTESLS DHRGGASNTT DAQVDSIVDP MLDLDIQELA SLTTGGGDVE NFERLFSKLK EMKDKAATLP HEQRKVHAEK VAKAFWMAIG GDRDEIEGLS SDEEH
-
Molecular Weight
34.5kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
AAGAB (ArfGAP with GTPase activity, ABR) is a member of the ArfGAP protein family, recognized for its critical role in regulating the actin cytoskeleton and endocytic traffic through its GTPase-activating protein (GAP) activity. Recent studies have highlighted AAGAB's involvement in various cellular processes, including cell migration, membrane trafficking, and signal transduction, implicating it in both normal physiological functions and pathological conditions such as cancer metastasis. Research into AAGAB has gained momentum due to its potential as a therapeutic target; alterations in its expression levels or activity have been linked to tumor progression and poor clinical outcomes in multiple cancer types. Additionally, its interaction with key signaling molecules, such as Rho GTPases, underscores its importance in cellular dynamics. Understanding the structure-function relationships of AAGAB, along with its intricate regulatory mechanisms, is essential for unraveling its role in cellular physiology and its potential implications in disease. Consequently, studies focusing on the recombinant expression of AAGAB allow for detailed investigation of its biochemical properties and interactions, paving the way for novel therapeutic strategies aimed at modulating its function in disease contexts. By exploring AAGAB’s functional mechanisms, researchers hope to elucidate its contributions to cancer biology and discover innovative approaches for intervention in cancer therapy.
